Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

cancer

24th Sep 2024

Plain language summary of the PERSEUS study on daratumumab combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma

25th Jul 2024

Plain Language Summary of amivantamab combined with chemotherapy in PAPILLON study for untreated EGFR-mutated non-small-cell lung cancer

The aim of this plain language review article is to help you to understand biosimilar medicines (called biosimilars) by giving a summary of biologic medicines and biosimilars. It is based on the experience of an international panel of physicians with expertise on biosimilars who discussed and agreed on the topics and information included in this review article. Biologic medicines are medicines that come from living organisms such as bacteria and animal or plant cells. Biosimilars are a group of approved biologic medicines that are similar to original biologic medicines that are already available. This review explains how biosimilars are developed and approved, and how they are used to treat people with cancer. It also answers some common important questions people with cancer might have when taking biosimilars.
22nd Jan 2024

Biosimilars and how they can be used to treat people with cancer- a plain language review

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy